Calypte Biomedical - 500 Beiträge pro Seite

[mgspecialist]

Hey Leute

Im folgendenden sollen Chancen, Tatsachen sowie weitere Fakten über das Unternehmen Calypte Biomedical erwähnt werden. So lets dicuss it!

909402

[DieNEUE]

FAKTEN:
http://www.marketguide.com/mgi/signdevt.asp?nss=www&rt=signd…
Signifikante Entwicklungsetappen
Calypte Biomedical Corp.
NASD : CALY
Sector: Technology
Industry: Scientific & Technical Instr.


 Calypte Biomedical Corp. Sells Minority Stake in Pepgen April 23, 2001
Calypte Biomedical Corp. announced that it has sold its 29% minority position in Pepgen Corporation, a privately held therapeutic company, for $500,000. Calypte`s decision to sell its Pepgen stake reflects the company`s commitment to its core diagnostics business and provides immediate access to cash needed to pay down debt and finance expenditures.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. Announces First Quarter Revenues and Status April 12, 2001
Calypte Biomedical Corp. announced that its preliminary first quarter revenues for the three months ended March 31, 2001 had exceeded its previous best quarter. At the same time, the Company stated that it does not believe that its currently-available financing will be adequate to sustain operations at current levels through the second quarter of 2001. In addition, the Company is currently in discussions with the staff of Nasdaq regarding the Company`s failure to meet the net tangible asset requirement for continued listing on the Nasdaq SmallCap Market set forth in the Nasdaq Marketplace Rules.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. In Distribution Pact February 06, 2001
Calypte Biomedical Corp. announced that beginning this month, Organon Teknika Corporation, a provider of in vitro diagnostics, will distribute worldwide an HIV-1 Western Blot serum (blood) assay manufactured by Calypte Biomedical. Organon Teknika will distribute the test non-exclusively under Calypte`s Cambridge Biotech tradename. The long-term arrangement calls for minimum monthly shipments, significantly increasing Calypte`s serum Western Blot sales volume.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. Alameda Manufacturing Facility Approved by FDA: Alameda Facility Will Allow Increased Production of HIV-1 Antibody Urine Test January 22, 2001
Calypte Biomedical Corp. announced that it has been granted "pre-market approval" by the U.S. Food and Drug Administration (FDA) for the production, effective immediately, of the Company`s HIV-1 Urine EIA product in its manufacturing plant in Alameda, California. The facility, which is equipped with updated manufacturing technology and is larger than Calypte`s current plant in Berkeley, will significantly increase the Company`s production and distribution capabilities.
--------------------------------------------------------------------------------
 International Studies Demonstrate Calypte Biomedical Corp.`s Modified HIV-1 Antibody Urine Test Competitive With Serum Testing December 20, 2000
Calypte Biomedical Corp. announced the results of two independent, international studies that examined the accuracy of the Company`s modified HIV-1 antibody urine test. Results of both studies of Calypte`s test demonstrated high concordance with serum (blood) testing, which has long been held to be the gold standard in HIV testing.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. New California Manufacturing Facility Gains State Approval - Company Expands Distribution Into Developing Countries December 20, 2000
Calypte Biomedical Corp. announced that its new manufacturing plant, based in Alameda, has received a Manufacturing License from the California Department of Health Services Food and Drug Branch. The California manufacturing license permits Calypte to manufacture its modified assay for worldwide export from its Alameda facility.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. and Becton, Dickinson and Company Announce New One-stop Testing Service December 04, 2000
Calypte Biomedical Corp. announced a joint promotional effort together with BD, whereby the companies are to co-promote the Sentinel family of testing services for urine-based testing for human immunodeficiency virus (HIV), chlamydia, and gonorrhea.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. Biomed, Osborn Science In Development Pact November 02, 2000
Calypte Biomedical Corp. announced that it is collaborating with the Osborn Scientific Group to develop two urine-based rapid HIV antibody tests. Once the assays are completed and have received regulatory clearance, Calypte and Osborn expect the products to be the first urine-based rapid HIV antibody tests.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that its HIV-1 antibody urine test has been approved by the State Drug Administration of the People`s Republic of China, making it the only urine-based HIV-1 test... August 24, 2000
Calypte Biomedical Corp. announced that its HIV-1 antibody urine test has been approved by the State Drug Administration of the People`s Republic of China, making it the only urine-based HIV-1 test approved for distribution within China. Calypte`s HIV urine test offers significant advantages over traditional HIV blood tests because unlike blood, no medical training is required to collect urine samples. In addition, the safety of both the patient and healthcare personnel are enhanced because the urine of HIV-infected people does not appear to harbor the infectious virus itself - only the harmless antibody that signifies prior exposure to HIV.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced the expansion of its innovative mobile HIV-1 antibody urine testing program from South Africa to 41 countries in sub-Saharan Africa. August 09, 2000
Calypte Biomedical Corp. announced the expansion of its innovative mobile HIV-1 antibody urine testing program from South Africa to 41 countries in sub-Saharan Africa.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that David Collins has replaced William Boeger as Chairman and Nancy Katz was appointed Chief Executive Officer. June 13, 2000
Calypte Biomedical Corp. announced that David Collins has replaced William Boeger as Chairman and Nancy Katz was appointed Chief Executive Officer.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced it has partnered with the Chinese National Center for AIDS Prevention and Control (NCAIDS) through Beijing HuaAi Science and Technology Development Co. Ltd. to... June 12, 2000
Calypte Biomedical Corp. announced it has partnered with the Chinese National Center for AIDS Prevention and Control (NCAIDS) through Beijing HuaAi Science and Technology Development Co. Ltd. to distribute the first HIV-1 antibody urine test within the People`s Republic of China. Once approved by the State Drug Administration of China (SDA), Calypte`s test will be the only urine-based HIV-1 test distributed within the People`s Republic of China. Calypte`s application has been submitted to the SDA and is currently in process, with approval expected by the end of 2000.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced today the appointment of American Edge Medical Company as the exclusive distributor of its urine HIV-1 antibody testing products in South Africa. American Edge... June 06, 2000
Calypte Biomedical Corp. announced today the appointment of American Edge Medical Company as the exclusive distributor of its urine HIV-1 antibody testing products in South Africa. American Edge has partnered with African Medical Solutions, a South African company formed specifically to market Calypte`s products in that country.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that it has entered into an exclusive distribution agreement with privately held Biobras S.A. of Brazil to distribute its HIV urine-based testing products... May 11, 2000
Calypte Biomedical Corp. announced that it has entered into an exclusive distribution agreement with privately held Biobras S.A. of Brazil to distribute its HIV urine-based testing products throughout Brazil.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that its Sentinel testing service, the first and only urine-based testing service dedicated exclusively to the detection of exposure to HIV-1, chlamydia, and... May 10, 2000
Calypte Biomedical Corp. announced that its Sentinel testing service, the first and only urine-based testing service dedicated exclusively to the detection of exposure to HIV-1, chlamydia, and gonorrhea sexually transmitted diseases (STDs), is now available throughout the United States. The service offers healthcare providers and patients a new fast, affordable and painless testing method for STDs. Calypte is developing a Sentinel testing service web site that will enable medical professionals and authorized institutions to order testing services directly over the Internet. The site is expected to be operational by May 12, 2000.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that Dr. Howard Urnovitz, Calypte`s Founder and Chief Scientific Officer, and William Boeger, Calypte`s Chairman, have established a new commercial company, named... March 09, 2000
Calypte Biomedical Corp. announced that Dr. Howard Urnovitz, Calypte`s Founder and Chief Scientific Officer, and William Boeger, Calypte`s Chairman, have established a new commercial company, named Chronix Biomedical, that will focus on novel ways to detect aberrant genes in individuals with chronic diseases. Chronix will be financed independently of Calypte, but Calypte will retain rights to any urine diagnostic tests that result from its research efforts. Both Dr. Urnovitz and Mr. Boeger will maintain their current positions at Calypte.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that it has entered into a collaboration with Wampole Laboratories, a division of Carter Wallace, Inc., and Clinical Reference Laboratory (CRL) to launch a new... January 24, 2000
Calypte Biomedical Corp. announced that it has entered into a collaboration with Wampole Laboratories, a division of Carter Wallace, Inc., and Clinical Reference Laboratory (CRL) to launch a new national urine-based testing service for HIV-1 antibody, chlamydia, and gonorrhea. The new service, called Sentinel, is a painless, non-invasive, urine-based sampling method designed to identify HIV-1 antibody and the chlamydia and gonorrhea sexually transmitted diseases (STDs).
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that the United States Food and Drug Administration approved a Day Assay license supplement to its "Cambridge Biotech" Human Immunodeficiency Virus Type 1 (HIV-1)... November 19, 1999
Calypte Biomedical Corp. announced that the United States Food and Drug Administration approved a Day Assay license supplement to its "Cambridge Biotech" Human Immunodeficiency Virus Type 1 (HIV-1) Western Blot test.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that it has signed a definitive distribution agreement that will give Carter-Wallace, Inc. the exclusive United States sales and marketing rights for the... September 16, 1999
Calypte Biomedical Corp. announced that it has signed a definitive distribution agreement that will give Carter-Wallace, Inc. the exclusive United States sales and marketing rights for the Company`s HIV products in the hospital, public health and reference lab markets. Terms were not announced.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that it has selected four new distributors for its urine HIV-1 screening EIA and Western blot supplemental tests. Together, the distributors will have exclusive... August 11, 1999
Calypte Biomedical Corp. announced that it has selected four new distributors for its urine HIV-1 screening EIA and Western blot supplemental tests. Together, the distributors will have exclusive distribution rights in 13 countries throughout the Middle East, Eastern Europe and Asia. Combined, the distribution agreements call for minimum purchases of 670,000 screening tests and more than 8, 000 Western blot supplemental tests.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that one of its newly acquired operating units, located in Rockville, Maryland, received a warning letter from the United States Food and Drug Administration. The... May 14, 1999
Calypte Biomedical Corp. announced that one of its newly acquired operating units, located in Rockville, Maryland, received a warning letter from the United States Food and Drug Administration. The warning letter was based upon an inspection of the Rockville manufacturing facility, which cited a number of significant observations. The facility was owned and operated at the time of the inspection by Cambridge Biotech Corp.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. and Carter-Wallace, Inc. announced that they have signed a letter of intent that will give Carter-Wallace the exclusive United States sales and marketing rights for Calypte... April 12, 1999
Calypte Biomedical Corp. and Carter-Wallace, Inc. announced that they have signed a letter of intent that will give Carter-Wallace the exclusive United States sales and marketing rights for Calypte Biomedical`s HIV products in the hospital, public health and reference lab markets.
--------------------------------------------------------------------------------
 The Chinese National Center for AIDS Prevention and Control announced that it has selected Calypte Biomedical Corp.`s non-invasive urine HIV test for wide-scale use within the Chinese health-care... March 11, 1999
The Chinese National Center for AIDS Prevention and Control announced that it has selected Calypte Biomedical Corp.`s non-invasive urine HIV test for wide-scale use within the Chinese health-care system.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that its affiliated therapeutic Company, Pepgen Corp., will begin Phase I clinical trials of its oral interferon, Interferon Tau, in multiple sclerosis patients. February 25, 1999
Calypte Biomedical Corp. announced that its affiliated therapeutic Company, Pepgen Corp., will begin Phase I clinical trials of its oral interferon, Interferon Tau, in multiple sclerosis patients.

[DieNEUE]

http://www2.stern.de/wissenschaft/wissen/journal/artikel_198…

Neue AIDS-Welle in USA befürchtet; Resistenzbildung gegen HIV in Afrika
Nkosi Johnson hatte zeitlebens gegen die
Isolierung Infizierter in Afrika gekämpft. Er
starb Freitag mit 12 Jahren an AIDS.


Amerikanische Studie warnt vor neuer AIDS-Welle in den USA
Die HIV-Infektionsraten in den USA nehmen wieder zu – dies zeigt eine alarmierende Studie, die eine besonders hohe Infektionsrate unter schwulen und bisexuellen jungen Männern ausmacht. Dabei erreichten die heutigen Infektionsraten in dieser Gruppe den gleichen Level wie in der Mitte der Achtzigerjahre, als die Epidemie ihre höchsten Ausmaße annahm.

Die Studie, die vom Center for Disease Control and Prevention zum 20. Jahrestag des Ausbruchs der Krankheit in Auftrag gegeben worden war, besagt, dass eine alarmierende Anzahl schwuler und bisexueller Männer zwischen 23 und 29 Jahren das HIV-Virus verbreiteten.

Wie die Studie an 3000 schwulen und bisexuellen jungen Männern in sechs Städten der USA zeigte, wurden im Schnitt 4,4 Prozent der Männer pro Jahr zwischen 1998 und 2000 neu infiziert. Dabei waren schwarze Männer wesentlich stärker betroffen: Bei ihnen lag die Neuinfektions-Rate bei 14,7 Prozent (im Gegensatz zu nur 2,5 Prozent bei weißen Männern) und ist damit durchaus vergleichbar zu Neuinfektionsraten in AIDS-Hochburgen Afrikas. Ein Drittel aller schwarzen schwulen und bisexuellen Männern in Amerika unter 30 sei HIV-positiv. Innerhalb der schwarzen Gemeinschaft halte die soziale Stigmatisierung gegenüber Schwulen und AIDS-Kranken die Männer von einem HIV-Test ab.

[the_Wolf]

Bringt den Wert über 40 Cent und ich bin dabei

[orpheo]

wolf

das denken sich mehr.
schau dir mal die umsätze vom freitag an.
das ding schiebt ggf schnell hoch.

[orpheo]

PS:
bin eigentlich kein pennystock fan.
aber hier habe ich mal ne ausnahme gemacht.

[thomas15]

@the_Wolf

40 cent....Du kannst am Montag einsteigen...
Die Eröffung am Montag dürfte um die 40 cent liegen.......

[xtimes]

Fakt ist z.B.!
Frage: Was verdient man damit?
Beispiel: Medikament "Combivir (AZT und Proteasehemmer)"
Hersteller ist Glaxo!
Fakt 1.Im Mai wurde vom Repräsentantenhaus der World Bank AIDS Marshall Plan Trust Fund Act angenommen, den Clinton im August als Global AIDS and Tuberculosis Relief Act of 2000 unterzeichnete. Er beinhaltet, der Weltbank über zwei Jahre verteilt 300 Millionen US-$ zu übergeben und den Jahresbetrag durch weitere Geldgeber auf 1 Milliarde US-$ aufstocken zu lassen.
Fakt 2.Bereits einen Tag nach dem Clinton-Erlaß stellten die Pharmakonzerne Boehringer Ingelheim, Bristol Myers Squibb, Glaxo, Hoffmann-LaRoche und Merck „deutlich reduziertePreise für HIV-Medikamente in Entwicklungsländen, besonders in Afrika" in Aussicht.
Fakt 3.Begleitet von UNAIDS machte allerdings nur Glaxo das konkrete Angebot einer mindestens 80%igen Preissenkung für COMBIVIR.
Fakt 4. Gleichzeitig rechnete eine Wirtschafts-Beratungsagentur aus, was sich dabei verdienen ließe.
Fakt 5.Ausgehend von einer 90%igen Preissenkung werden im Jahr 2004 "allein" für COMBIVIR auf den „emerging markets" Indien, Thailand, China, Brasilien und Südafrika 6,3 MILLIARDEN US-$ vorhergesagt.


Dabei wird COMBIVIR doch "nur" bei HIV- infizierten angewendet, der Caly-Test aber vom Kleinkind bis zum Greis!
COMBIVIR kostet pro Behandlungstag "nur" 2 Us/$!!!!!!!

[orpheo]

xtimes,
interessant.

hast Du eine ahnung, was ein Calypte-test kostet?
ist er patentgeschützt? (obwohl ich glaube, dass
solcherlei probleme ggf durch aufkauf gelöst werden)

was ich momentan nicht verstehe, ist, dass sich nicht
einfach einer der pharmariesen den laden einverleibt.

alles <$50mio ist doch portokasse.

wo ist der haken?

[DieNEUE]

orpheo
Das ist das Große Rätsel.
Was bietet ein Pharma Rise pro Aktie.
1$
2$
3$
4$

xtimes Due las fundamentaler Profie (Den Eindruck machst Du auf mich )
xtimes Was kostet ein Caly Test und kann man den auch in Germany machen ?
Gibt es hier einen Dr. Med. im Board ?
MfG
DN

[xtimes]

Gerüchte sagen der Test kostet 3 Dollar pro Person!
Leider will man anfragen bezüglich des Preises nicht beantwortet.
Das beispiel "combivir" beinhaltet die Märkte die Calypte ebenfalls erschlossen hat, oder anstrebt den Test in diesen Ländern zu vertreiben.